Zenith Drugs Ratios

Zenith Drugs Ltd Ratios

The Zenith Drugs Ltd Ratios page provides a complete fundamental analysis of Zenith Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Zenith Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Zenith Drugs Ltd (NSE: ZENITHDRUG, BSE: 92356) is currently trading at ₹39.95, with a market capitalization of ₹653.37M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Zenith Drugs Ltd remains a key stock for fundamental analysis using Zenith Drugs Ltd Ratios.

Zenith Drugs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Zenith Drugs Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Zenith Drugs Ltd Ratios.

Historically, the Zenith Drugs Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Zenith Drugs Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Zenith Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Zenith Drugs Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Zenith Drugs Ltd P/S ratio currently stands at 0, an important part of Zenith Drugs Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

A stable or declining Zenith Drugs Ltd P/S ratio indicates cautious market sentiment.

Zenith Drugs Ltd Price to Cash Flow Ratio (P/CF)

The Zenith Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Zenith Drugs Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Zenith Drugs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Zenith Drugs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Zenith Drugs Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Zenith Drugs Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Zenith Drugs Ltd EV/EBITDA ratio is currently 0, a key metric in Zenith Drugs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Zenith Drugs Ltd EV/EBITDA indicates balanced valuation.

Zenith Drugs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Zenith Drugs Ltd D/E ratio is currently 0.70, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.70
• 2023: 0.38
• 2022: 1.51
• 2021: 1.56

Zenith Drugs Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Zenith Drugs Ltd ROE currently stands at 10.88%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 10.88
• 2023: 24
• 2022: 35.13
• 2021: 29.83

Zenith Drugs Ltd maintains stable profitability levels.

Zenith Drugs Ltd Ratios Analysis Summary

The Zenith Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Zenith Drugs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Zenith Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.